{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Cancer&page=23", "query": { "condition": "Lung Cancer", "page": 23 }, "page_size": 10 }, "pagination": { "page": 23, "page_size": 10, "total_count": 5910, "total_pages": 591, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Cancer&page=24&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Cancer&page=22&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T18:50:04.456Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05349227", "title": "Comprehensive Outcomes for After Cancer Health", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Ovarian Cancer", "Breast Cancer", "Lung Cancer", "Gastric Cancer", "Survivorship", "Endometrial Cancer", "Head and Neck Cancers", "Prostate Cancers", "Geriatric Oncology", "Metastatic Breast Cancer", "Metastatic Cancer" ], "interventions": [ { "name": "Digital Health Coaching Program", "type": "BEHAVIORAL" }, { "name": "Fitbit", "type": "DEVICE" } ], "intervention_types": [ "BEHAVIORAL", "DEVICE" ], "sponsor": "Pack Health", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 625, "start_date": "2022-06-23", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2024-12-11", "last_synced_at": "2026-10-26T18:50:04.456Z", "location_count": 7, "location_summary": "Gainesville, Florida • Boston, Massachusetts • Omaha, Nebraska + 3 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05349227" }, { "nct_id": "NCT00430261", "title": "Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer", "Adenocarcinoma" ], "interventions": [ { "name": "sunitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Swedish Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2007-01", "completion_date": "2010-10", "has_results": false, "last_update_posted_date": "2010-10-06", "last_synced_at": "2026-10-26T18:50:04.456Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00430261" }, { "nct_id": "NCT07806773", "title": "Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "NSCLC", "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "TUB-040", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2026-11", "completion_date": "2029-05", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-26T18:50:04.456Z", "location_count": 2, "location_summary": "Los Angeles, California • East Brunswick, New Jersey", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "East Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT07806773" }, { "nct_id": "NCT05635266", "title": "Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Age-Related Macular Degeneration", "Allergies", "Alpha-Gal Syndrome", "Alzheimer Disease", "Amyloidosis", "Ankylosing Spondylitis", "Arthritis", "Alopecia Areata", "Asthma", "Atopic Dermatitis", "Autism", "Autoimmune Hepatitis", "Behcet's Disease", "Beta-Thalassemia", "Cancer", "Celiac Disease", "Kidney Diseases", "COPD", "Crohn Disease", "Cystic Fibrosis", "Diabetes", "Dravet Syndrome", "DMD", "Fibromyalgia", "Graves Disease", "Thyroid Diseases", "Hepatitis", "Hidradenitis Suppurativa", "ITP", "Leukemia", "ALS", "Lupus or SLE", "Lymphoma", "Multiple Sclerosis", "Myasthenia Gravis", "Heart Diseases", "Parkinson Disease", "Pemphigus Vulgaris", "Cirrhosis", "Psoriasis", "Schizophrenia", "Scleroderma", "Sickle Cell Disease", "Stroke", "Ulcerative Colitis", "Vasculitis", "Vitiligo" ], "interventions": [ { "name": "Specimen sample", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Sanguine Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 20000, "start_date": "2021-10-26", "completion_date": "2025-10", "has_results": false, "last_update_posted_date": "2024-05-07", "last_synced_at": "2026-10-26T18:50:04.456Z", "location_count": 1, "location_summary": "Waltham, Massachusetts", "locations": [ { "city": "Waltham", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05635266" }, { "nct_id": "NCT02715102", "title": "Circulating Tumor DNA in Patients at High Risk for Lung Cancer", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer of the Lung", "Lung Cancer", "Lung Neoplasms", "Adenocarcinoma of the Lung", "Non Small Cell Carcinoma of the Lung", "Small Cell Carcinoma of the Lung" ], "interventions": [], "intervention_types": [], "sponsor": "Pathway Genomics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2016-06", "completion_date": "2017-08", "has_results": false, "last_update_posted_date": "2017-08-21", "last_synced_at": "2026-10-26T18:50:04.456Z", "location_count": 1, "location_summary": "Santa Monica, California", "locations": [ { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02715102" }, { "nct_id": "NCT04449874", "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer", "Colorectal Cancer", "Advanced Solid Tumors" ], "interventions": [ { "name": "GDC-6036", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "GDC-1971", "type": "DRUG" }, { "name": "Inavolisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 498, "start_date": "2020-07-29", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-26T18:50:04.456Z", "location_count": 9, "location_summary": "Duarte, California • La Jolla, California • Orange, California + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04449874" }, { "nct_id": "NCT06712810", "title": "Q702 for the Treatment of Patients With Hematologic Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematopoietic and Lymphatic System Neoplasm", "Histiocytic Sarcoma", "Malignant Histiocytosis", "Peripheral T-Cell Lymphoma, Not Otherwise Specified", "Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Chronic Myelomonocytic Leukemia", "Recurrent Follicular Lymphoma", "Recurrent Langerhans Cell Histiocytosis", "Recurrent Lymphoplasmacytic Lymphoma", "Recurrent Myelodysplastic Syndrome", "Recurrent Myelofibrosis", "Recurrent Small Lymphocytic Lymphoma", "Recurrent Waldenstrom Macroglobulinemia", "Refractory Chronic Lymphocytic Leukemia", "Refractory Chronic Myelomonocytic Leukemia", "Refractory Erdheim-Chester Disease", "Refractory Follicular Lymphoma", "Refractory Langerhans Cell Histiocytosis", "Refractory Lymphoplasmacytic Lymphoma", "Refractory Myelodysplastic Syndrome", "Refractory Myelofibrosis", "Refractory Small Lymphocytic Lymphoma", "Refractory Waldenstrom Macroglobulinemia", "Rosai-Dorfman-Destombes Disease", "Primary Central Nervous System Lymphoma", "Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm", "Recurrent Erdheim-Chester Disease", "Recurrent Fibroblastic Reticular Cell Sarcoma", "Recurrent Histiocytic Sarcoma", "Recurrent Interdigitating Dendritic Cell Sarcoma", "Recurrent Rosai-Dorfman-Destombes Disease", "Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm", "Refractory Fibroblastic Reticular Cell Sarcoma", "Refractory Histiocytic Sarcoma", "Refractory Interdigitating Dendritic Cell Sarcoma", "Refractory Rosai-Dorfman-Destombes Disease" ], "interventions": [ { "name": "Axl/Mer/CSF1R Inhibitor Q702", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2025-08-27", "completion_date": "2030-09-15", "has_results": false, "last_update_posted_date": "2025-10-10", "last_synced_at": "2026-10-26T18:50:04.456Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06712810" }, { "nct_id": "NCT00975182", "title": "A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Squamous Non-Small Cell Lung Cancer, Solid Cancers" ], "interventions": [ { "name": "GDC-0941", "type": "DRUG" }, { "name": "erlotinib HCl", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2009-09", "completion_date": "2014-09", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-10-26T18:50:04.456Z", "location_count": 2, "location_summary": "Aurora, Colorado • New Brunswick, New Jersey", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00975182" }, { "nct_id": "NCT04372524", "title": "Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Graft-versus-Host-Disease", "Leukemia", "Allogeneic Hematopoietic Stem Cell Transplantation", "Blood Cancer", "Non-Malignant Hematologic and Lymphocytic Disorder" ], "interventions": [], "intervention_types": [], "sponsor": "University of British Columbia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "24 Years", "sex": "ALL", "summary": "0 Years to 24 Years" }, "enrollment_count": 350, "start_date": "2020-11-15", "completion_date": "2025-01", "has_results": false, "last_update_posted_date": "2023-12-05", "last_synced_at": "2026-10-26T18:50:04.456Z", "location_count": 11, "location_summary": "San Francisco, California • Denver, Colorado • Atlanta, Georgia + 8 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04372524" }, { "nct_id": "NCT07278479", "title": "Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Large Cell Neuroendocrine Carcinoma", "Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)", "Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)", "Small Cell Lung Cancer (SCLC)", "Gastroenteropancreatic NEC (GEP NEC)", "NEC of the Bladder", "Other DLL3 Expressing epNEC" ], "interventions": [ { "name": "[212Pb]Pb-MP0712", "type": "DRUG" }, { "name": "[203Pb]Pb-MP0712", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Molecular Partners AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 138, "start_date": "2026-05-18", "completion_date": "2032-09", "has_results": false, "last_update_posted_date": "2026-10-21", "last_synced_at": "2026-10-26T18:50:04.456Z", "location_count": 8, "location_summary": "Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 5 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Glen Burnie", "state": "Maryland" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT07278479" } ] }